Aclaris Therapeutics (ACRS) vs REGENXBIO (RGNX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Aclaris Therapeutics (ACRS) has outperformed REGENXBIO (RGNX) over the past year, gaining 99.5% versus a loss of 33.8%. Over five years, ACRS leads with a -77.5% price change compared with -77.5% for RGNX. Aclaris Therapeutics is the larger company by market cap ($557.9 million vs $534.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACRS | RGNX |
|---|---|---|
| Share price | $3.79 | $8.09 |
| Market cap | $557.88M | $534.05M |
| 1-day change | +11.47% | +6.52% |
| YTD return | +25.91% | -43.82% |
| 1-year return | +99.47% | -33.80% |
| 5-year return | -77.45% | -77.50% |
| EPS (TTM) | $-0.58 | $-3.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.60 | $16.19 |
| 52-week low | $1.74 | $5.46 |
| Distance from 52-week high | -42.58% | -50.03% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +168.60% | +191.47% |
| Average volume | 2.59M | 1.53M |
| Shares outstanding | 147.20M | 66.01M |
| Employees | 69 | 371 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACRS has outperformed RGNX by 133.3 percentage points over the past year.
- The two companies sit in different sectors: Aclaris Therapeutics in Health Care and REGENXBIO in Healthcare.
About Aclaris Therapeutics
ACRS stock →Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About REGENXBIO
RGNX stock →REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.
Healthcare · Biotechnology · 371 employees
ACRS vs RGNX FAQ
Which is bigger, Aclaris Therapeutics or REGENXBIO?
Aclaris Therapeutics (ACRS) is larger, with a market capitalization of $557.88M compared with $534.05M for REGENXBIO (RGNX).
Which stock has performed better over the past year, ACRS or RGNX?
ACRS returned +99.47% over the past 12 months, compared with -33.80% for RGNX (price return, excluding dividends). Past performance does not predict future results.
Are Aclaris Therapeutics and REGENXBIO in the same industry?
No. Aclaris Therapeutics is in the Health Care sector, while REGENXBIO is in Healthcare.